1.54
Neurosense Therapeutics Ltd stock is traded at $1.54, with a volume of 140.64K.
It is up +2.67% in the last 24 hours and up +58.76% over the past month.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
See More
Previous Close:
$1.50
Open:
$1.52
24h Volume:
140.64K
Relative Volume:
0.79
Market Cap:
$36.94M
Revenue:
-
Net Income/Loss:
$-13.76M
P/E Ratio:
-1.6559
EPS:
-0.93
Net Cash Flow:
-
1W Performance:
+1.32%
1M Performance:
+58.76%
6M Performance:
+57.13%
1Y Performance:
+42.59%
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Name
Neurosense Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare NRSN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
NRSN
Neurosense Therapeutics Ltd
|
1.54 | 36.46M | 0 | -13.76M | 0 | -0.93 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Neurosense Therapeutics Ltd Stock (NRSN) Latest News
NRSN stock touches 52-week high at $1.52 amid growth optimism - Investing.com Australia
D. Boral Capital Begins Coverage on NeuroSense Therapeutics (NASDAQ:NRSN) - Defense World
D. Boral Capital Initiates Coverage of NeuroSense Therapeutics (NRSN) with Buy Recommendation - Nasdaq
Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst InsightsNeuroSense Therapeutics (NASDAQ:NRSN) - Benzinga
Boral Capital starts NeuroSense stock with Buy, $14 target By Investing.com - Investing.com South Africa
This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday - Benzinga
NeuroSense (NRSN) Receives Buy Rating with Promising Outlook | N - GuruFocus
Boral Capital starts NeuroSense stock with Buy, $14 target - Investing.com
NeuroSense Completes PrimeC Manufacturing Scale-Up for Canadian Launch - TipRanks
NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch - Nasdaq
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement - ADVFN
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND - ADVFN
NeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Down 0.9% – Here’s Why - Defense World
NeuroSense Therapeutics Advances ALS Treatment and Strategic Partnership - TipRanks
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update - Quantisnow
Head-To-Head Contrast: NeuroSense Therapeutics (NASDAQ:NRSN) versus TFF Pharmaceuticals (NASDAQ:TFFP) - Defense World
NLS and Kadimastem: Swiss-israeli merger in ALS - European Biotechnology Magazine
Neurosense Therapeutics Announces Phase 2B Microrna Data - marketscreener.com
Groundbreaking ALS Treatment Cuts Disease Progression by 33%, Boosts Survival 58% - Stock Titan
NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment - PR Newswire
NeuroSense Therapeutics Reports 2024 Financial Results - TipRanks
NeuroSense Therapeutics Reports 2024 Financial Results and Advances ALS Treatment - MSN
NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates - The Malaysian Reserve
NeuroSense’s ALS drug PrimeC shows success in phase 2b, eyes final trial - MSN
Breakthrough ALS Treatment Shows Disease-Modifying Results in Phase 2b Trial - Stock Titan
NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting - PR Newswire
Lou Gehrig's Disease Pipeline: 75+ Innovators Pioneering Breakthrough Therapies | DelveInsight - openPR.com
NeuroSense Updates on Pharmaceutical Partnership Discussions - TipRanks
Amyotrophic Lateral Sclerosis Pipeline: Advancing the Future with 50+ Innovators Leading Breakthrough Therapies - openPR.com
Market Alert: Hinge Health's Multi-Billion Dollar Expected IPO Highlights 600% Valuation Opportunity for DarioHealth - Business Wire
Motor Neuron Disease Clinical Pipeline | 180+ Companies Advancing Next-Generation Therapies - openPR.com
NeuroSense Therapeutics (NRSN) to Release Earnings on Monday - Defense World
NeuroSense Therapeutics: A Promising Biotech Stock in the Neurodegenerative Space - eng.expertclub.ge
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug - Business Wire
NeuroSense Advances PrimeC Commercialization in Canada - TipRanks
PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape - Marketscreener.com
Breakthrough: NeuroSense ALS Treatment Cuts Disease Progression by 36%, Boosts Survival 43% - StockTitan
The next rare disease roadblock: American innovation moving ex-U.S. - BioCentury
NeuroSense Therapeutics Reports Positive Phase 2b Study Results for ALS Treatment - TipRanks
Neurosense Therapeutics Ltd Stock (NRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):